NCT05063565 2026-03-02
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT07305428 2025-12-26
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
The University of Hong Kong
Phase NA Recruiting
NCT07154082 2025-09-04
Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
Tongji Hospital
Phase 2 Recruiting
NCT06205732 2024-01-16
A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.
Qianfoshan Hospital
Unknown
NCT03864211 2022-09-29
Thermal Ablation Followed by Immunotherapy for HCC
Xiangya Hospital of Central South University
Phase 1/2 Unknown
NCT04174781 2022-06-09
Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC
Zhejiang University
Phase 2 Unknown
NCT05240404 2022-02-15
Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
Xiangya Hospital of Central South University
Phase 2 Unknown
NCT04653389 2022-01-11
Perioperative Therapy for Hepatocellular Carcinoma
Zhejiang University
Phase 2 Terminated
NCT04981665 2022-01-05
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
Zhejiang University
Phase 2 Unknown
NCT02989870 2020-06-05
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT00610389 2010-05-10
Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Unknown